SRR5088930
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- APICAL_SURFACE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- COMPLEMENT+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
- INFLAMMATORY_RESPONSE+0.200
Top 10 suppressed
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.400
- ANDROGEN_RESPONSE-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- TGF_BETA_SIGNALING-0.300
- UV_RESPONSE_DN-0.300
- ANGIOGENESIS-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- DNA_REPAIR-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290925 | — | — | 0.846 |
| 2 | d3be84d5-9dd7-4366-9aea-532dc76f19ba | — | — | 0.837 |
| 3 | R13 | — | — | 0.788 |
| 4 | 6e0c14ea-3eb3-424a-bc12-fb127ac1a777 | — | — | 0.772 |
| 5 | R49 | — | — | 0.772 |
| 6 | R238 | — | — | 0.769 |
| 7 | TCGA-AC-A5XS-01A-11R-A29R-07 | — | B | 0.757 |
| 8 | SRR10900009 | — | — | 0.754 |
| 9 | BS_2R9TCR03 | low-grade glioma | — | 0.753 |
| 10 | TCGA-A8-A09Z-01A-11R-A00Z-07 | — | B | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |